RIVER-81
ClinicalTrials.gov ID NCT06191263
Title:
A Multicenter, Open-Label, Dose-Finding Clinical Trial to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Efficacy of RVU120 in Combination With Venetoclax in Participants With Acute Myeloid Leukemia Who Failed Prior Therapy With Ventoclax and a Hypomethylating Agent
Study population:
Women and man 18 Years and older
Study design:
In Part 1 dose-escalation participants will receive escalating oral doses of RVU120 starting at 125 mg administered every other day on days 1-13, and escalating oral doses of venetoclax starting with 200 mg administered daily on days 1-14 of each 21-day cycle of treatment. The recommended doses for further study will be based on the observed safety, tolerance, PK and PD.
In Part 2, it will be assessed whether the recommended dose level from Part 1 reaches the targetted response criteria, and if reached, Part 3 will be initiated to evaluate further the efficacy and safety of the recommended doses in a larger population.
Intervention/treatment:
RVU120, Venetoclax
Eligibility criteria:
Inclusion Criteria
- Patients must have a diagnosis of AML (per 2022 WHO classification)
- Patients must have relapsed or refractory AML (per ELN 2022 criteria)
- Patients must have failed first-line treatment with venetoclax combined with a hypomethylating agent
- Patients must have no alternative therapeutic options likely to produce clinical benefit
- Patients must have ECOG performance status of 0 to 2
- Patients must have adequate end organ function defined as:
- WBC < 25 x 10(9)/L on Day 1 prior to first dose of study drug
- Platelet count > 10,000/mcL on Day 1 prior to first dose of study drug
- AST (aspartate transaminase) and ALT (alanine transaminase) ≤ 3 x ULN (upper limit of normal)
- Total bilirubin ≤ 3 x ULN
- Creatinine clearance (Cockcroft & Gault formula) ≥ 50 mL/min
- LVEF (left ventricular ejection fraction) ≥ 40% by electrocardiography
- Subjects must have the ability to understand and the willingness to sign a written informed consent document and complete study related procedures
Exclusion Criteria
- APL (acute promyelocytic leukemia), the M3 subtype of AML
- Active CNS (central nervous system) leukemia
- Previous treatment with CDK8 and/or CDK19-targeted therapy
- Major surgery within 28 days prior to the first dose of study drug
- Hematopoietic stem cell transplant within 120 days prior to the first dose of study drug
- Currently pregnant or breast-feeding. Females of child bearing potential must have a negative serum pregnancy test within 72 hours prior to the first dose of study drug
- Uncontrolled intercurrent illness that could limit life expectancy or ability to complete study correlates. This includes but is not limited to:
- Active, Grade ≥2 acute GVHD (graft versus host disease) or requirement for systemic immunosuppressive medication for GVHD
- Evidence of ongoing or uncontrolled systemic bacterial, fungal or viral infection and acute inflammatory conditions (including pancreatitis)
- Ongoing significant liver disease such as cirrhosis, drug-induced liver injury, active hepatitis, or chronic persistent hepatitis B and/or hepatitis C
- Ongoing drug-induced pneumonitis
- Significant cardiac dysfunction, defined as myocardial infarction within 12 months prior to the first dose of study drug, NYHA (New York Heart Association) Class III or IV heart failure, uncontrolled dysrhythmias, poorly controlled angina
- History of ventricular arrhythmia or QTc ≥ 470 ms (Bazett’s formula)
- Prior history of malignancies other than AML, unless disease-free for 5 years or more or prior basal cell carcinoma of the skin, non-metastatic squamous cell carcinoma of the skin, carcinoma in situ of cervix, breast or bladder, and incidental histological finding of prostate cancer (TMN stage T1a or T1b)
- Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RVU120 and/or venetoclax
- Taking any medications, herbal supplements, or other substances (including smoking that are known to be strong inhibitors or moderate/strong inducers or sensitive substrates of CYP1A2
- Taking any medications, over-the-counter medications, foods or herbal supplements that are known to be strong or moderate inhibitors of CYP3A4 or P-gp (P-glycoprotein)
- Known allergy or hypersensitivity to any component of RVU120 or venetoclax formulations
Participation criteria are verified by the investigator. Participation in the study is contingent upon meeting all inclusion criteria and meeting none of the exclusion criteria. The criteria provided may not be a complete list.
Contact and locations:
Main Researcher |
Institution |
Adress |
Phone |
|
Status |
| Krzysztof Mądry, MD PhD | MTZ Clinical Research powered by Pratia | Gładka 22 02-172 Warszawa, Poland |
+48 669494678 | [email protected] | |
| Aleksandra Butrym, Prof. | Specjalistyczny Szpital im. Dr A. Sokołowskiego w Wałbrzychu | Sokołowskiego 4 58-309 Wałbrzych, Poland |
+48 746489736 | [email protected] | |
| Piotr Centkowski, MD PhD | KO-MED Nova Sp. z o.o. Ośrodek Badań Klinicznych w Białej Podlaskiej | ul. Terebelska 57-65 21-500 Biała Podlaska, Poland |
+48 603314074, +48 833067700 |
[email protected], [email protected] | |
| Jarosław Dybko, MD PhD | Dolnośląskie Centrum Onkologii, Pulmonologii i Hematologii we Wrocławiu | ul. Grabiszyńska 105 53-439 Wrocław, Poland |
+48 782999717 | [email protected] | |
| Witold Prejzner, MD PhD | Uniwersyteckie Centrum Kliniczne, Klinika Hematologii i Transplantologii |
ul. Smoluchowskiego 17 80-214 Gdańsk, Poland |
+48 585844340 | [email protected] | |
| Krzysztof Gawroński, MD PhD | Wojskowy Instytut Medyczny – Państwowy Instytut Badawczy | ul. Szaserów 128 01-141 Warszawa, Poland |
+48261817013 | [email protected] | |
| Ewa Lech-Marańda, Prof. | Instytut Hematologii i Transplantologii | ul. Indiry Gandhi 14 20-776 Warszawa, Poland |
|||
| Emilian Snarski, Prof. | Szpital Uniwersytecki im. Karola Marcinkowskiego | ul. Zyty 26 65-046 Zielona Góra, Poland |
+48683296371 | [email protected] | |
| Marcin Rymko, MD PhD | Wojewódzki Szpital Zespolony im. Ludwika Rydygiera w Toruniu | ul. Św. Józefa 53-59 87-100 Toruń, Poland |
|||
| Giovanni Marconi, MD PhD/ Maria Gannini, MD PhD |
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori – IRST IRCCS | Via Piero Maroncelli 40 Meldola, Italy | +39 0543739100 | [email protected] | |
| Adriano Venditti, Prof. | Universita Degli Studi di Roma “Tor Vergata” – Facolta di Medicina e Chirurgia |
Viale Oxford, 81
Rome, Italy
|
|||
| Cristina Papayannidis, MD PhD | Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi |
Via Giuseppe Massarenti 9, padiglione 8, Bologna, Italy
|
|||
| Erika Borlenghi, MD PhD | Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia | Piazzale Spedali Civili 1 Brescia, Italy |
+39 0303995438 | [email protected] | |
| Ernesta Audisio, MD PhD | Azienda Ospedaliera Universitaria Citta Della Salute E Della Scienza Di Torino | Corso Bramante 88 Turin, Italy |
+39 0116335551 | [email protected] | |
| Debora Capelli, MD PhD | Azienda Ospedaliero Universitaria Delle Marche | Via Conca 71 Ancona, Italy |
+39 0715963930 | [email protected] | |
| Nicola Di Renzo, MD PhD | Ospedale Vito Fazzi Lecce | Piazza Filippo Muratore 1 Lecce, Italy |
+39 0832 661923 | [email protected] | |
| Irene Sanchez Vadillo, MD PhD | Hospital Universitario La Paz |
Paseo de la Castellana 261 Madrid, Spain
|
|||
| Sara Garcia Avila, MD PhD | Hospital del Mar |
Hospital del Mar Passeig Maritim 25-29 Barcelona, Spain
|
|||
| Adolfo de la Fuente, MD PhD | MD Anderson Cancer Center Madrid |
Calle Arturo Soria, No. 270 Madrid, Spain
|
|||
| Alejandro Contento Gonzalo, MD PhD | Hospital Regional Universitario de Málaga – Hospital General |
Avenida Carlos Haya s/n Málaga, Spain
|
|||
| Ana Alfonso Pierola, MD PhD | Clinica Universidad de Navarra |
Avenue Pio XII 36
Pamplona, Spain |
|||
| Guadalupe Oñate, MD PhD | Hospital De La Santa Creu I Sant Pau |
Carrer De San Quinti 89
Barcelona, Spain
|
|||
| Pau Montesinos Fernández, MD PhD | Hospital Universitario Y Politecnico La Fe |
Avenida De Fernando Abril Martorell 106
Valencia, Spain
|
|||
| Montserrat Arnan Sangerman, MD PhD | Institut Catala D’oncologia |
Avinguda De La Gran Via De L’hospitalet 199-203 Llobregat, Spain
|
|||
| José Antonio Pérez Simón, MD PhD | University Hospital Virgen Del Rocio S.L. |
Avenida De Manuel Siurot S/n
Sevilla, Spain
|
|||
| Juan Miguel Bergua Burgues, MD PhD | Hospital San Pedro De Alcantara |
Avenida De Pablo Naranjo Porras S/n
Caceres, Spain
|
|||
| Sylvain Garciaz, MD PhD | Institut Paoli-Calmettes |
232 Boulevard De Sainte Marguerite
Marseille, France
|
|||
| Stefan Wickenhauser, MD PhD | Centre Hospitalier Universitaire De Nimes |
Place Du Professeur Robert Debre
Nimes, France
|
|||
| Claude-Eric Bulabois, MD PhD | Centre Hospitalier Universitaire Grenoble Alpes |
Boulevard De La Chantourne
Grenoble, France
|
|||
| Kamel Laribi, MD PhD | Centre Hospitalier Le Mans |
194 Avenue Rubillard
Le Mans, France
|
|||
| Laure Goursaud, MD PhD | Centre Hospitalier Universitaire De Lille |
Rue Michel Polonowski
Lille, France
|
|||
| Emilie Lemasle Hue, MD PhD | Centre Henri Becquerel |
1 Rue D Amiens
Rouen, France
|
|||
| Thomas Cluzeau, MD PhD | Centre Hospitalier Universitaire De Nice |
151 Route De Saint Antoine
Nice, France
|
|||
| Pierre Fenaux, MD PhD | Assistance Publique Hopitaux De Paris |
1 Avenue Claude Vellefaux
Paris, France
|